Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | BAX | Q07812 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6933176 | 0.89 | KDM4E (0.45) | HDAC1HDAC2KDM4EFFAR4 | |
| SCHEMBL8312881 | 0.89 | KDM4E (0.45) | HDAC1HDAC2KDM4EFFAR4 | |
| SCHEMBL7987827 | 0.74 | LTA4H (0.41) | LTA4HPLA2G2APPARGTAAR1FFAR4 | |
| SCHEMBL8671305 | 0.69 | LTA4H (0.75) | LTA4HPLA2G2APPARATAAR1PKM | |
| SCHEMBL16976445 | 0.69 | LTA4H (0.51) | LTA4HPLA2G2A | |
| SCHEMBL16950232 | 0.67 | TAAR1 (0.43) | PPARGTAAR1 | |
| SCHEMBL2296317 | 0.66 | ALDH1A1 (0.83) | LTA4HPLA2G2APPARAPKMNR1H2 | |
| SCHEMBL8730007 | 0.66 | LTA4H (0.64) | LTA4HPLA2G2APPARAHDAC1HDAC2 | |
| SCHEMBL9902586 | 0.65 | LTA4H (0.63) | LTA4HPLA2G2APPARA | |
| SCHEMBL10583018 | 0.65 | LTA4H (0.69) | LTA4HPLA2G2APPARAHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6136832-A | RACEMIC MIXTURES AND ENANTIOMORPHS | OXIS INTERNATIONAL INC. (US) | 2000-10-24 | — | — | US | claimed |
| EP-0938482-A1 | 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR | Oxis International, Inc. (US) | 1999-09-01 | — | — | EP | claimed |
| WO-1998007714-A1 | 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR | OXIS INTERNATIONAL, INC. (US) | 1998-02-26 | — | — | WO | claimed |
| EP-1246811-B1 | METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES | OXIS ISLE OF MAN LTD (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-6613919-B2 | Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones | OXIS ISLE OF MAN | 2003-09-02 | — | — | US | disclosed |
| US-20030065196-A1 | Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones | OXIS ISLE OF MAN | 2003-04-03 | — | — | US | disclosed |
| EP-1246811-A1 | METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES | OXIS Isle of Man, Limited (GB) | 2002-10-09 | — | — | EP | disclosed |
| US-6262073-B1 | INHIBITING THE ACTION OF A PRO-INFLAMMATORY CYTOKINE | OXIS INTERNATIONAL INC. | 2001-07-17 | — | — | US | disclosed |
| WO-2001049671-A1 | METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES | OXIS ISLE OF MAN, LIMITED (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6136832-A | RACEMIC MIXTURES AND ENANTIOMORPHS | OXIS INTERNATIONAL INC. (US) | 2000-10-24 | — | — | US | disclosed |
| US-6005000-A | 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor | OXIS INTERNATIONAL, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0938482-A1 | 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR | Oxis International, Inc. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998007714-A1 | 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR | OXIS INTERNATIONAL, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065196-A1 | Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones | ADH1C, SRD5A2, SRD5A1 | LTA4H 245/4885PLA2G2A 2035/4885PPARA 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.